The Meso Foundation is optimistic about the results of the Phase 1b trial of pembrolizumab for PD-L1-positive advanced solid tumors, which were announced at the…
1717 K Street NW, Suite 900
Washington, DC 20006-5349
(877) 363-6376
HELPLINE
